Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Quanex Building Products Corporation due to allegations of misleading statements and operational issues that have negatively impacted the company's financial performance [2][4]. Financial Performance - Quanex reported a diluted EPS of ($6.04) for Q3 2025, a significant decline from $0.77 in the same period the previous year [5]. - The company disclosed operational issues related to the Tyman business in Mexico, which impacted results more than expected during Q3 2025 [5]. - Adjusted EBITDA for the company was reported at $70.30 million [5]. Operational Issues - The complaint alleges that Quanex's tooling and equipment maintenance procedures in its Tyman Mexico facility were significantly underinvested, leading to degraded conditions [4]. - CEO George Wilson indicated that operational challenges in the Tyman facility negatively impacted EBITDA in the Hardware Solutions segment by almost $5 million in Q3 2025 [6]. - The issues were identified midyear, and the systems for anticipating and planning tooling repairs were described as significantly deficient [6]. Stock Market Reaction - Following the announcement of the financial results, Quanex's stock price fell by $2.73, or 13.1%, closing at $18.18 per share on September 5, 2025 [6]. - The stock continued to decline, falling by $1.98, or 10.9%, to close at $16.20 per share on September 8, 2025 [6]. Legal Proceedings - Investors who suffered losses exceeding $75,000 in Quanex between December 12, 2024, and September 5, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1][2]. - The deadline to seek the role of lead plaintiff in the federal securities class action against Quanex is November 18, 2025 [2].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has led to significant investor losses [1][3]. Summary by Relevant Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Baxter between February 23, 2022, and July 30, 2025, to discuss their legal rights [1]. - The firm has set a deadline of December 15, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Baxter [1]. Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which caused malfunctions and posed risks to patients [3]. - Specific issues included underinfusion, overinfusion, and complete non-delivery of fluids, which led to serious injuries and deaths [3]. - Baxter's attempts to address these defects were deemed inadequate, and the company faced a heightened risk of halting sales of the Novum LVP [3]. Impact on Stock Performance - The extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [4]. Class Action Participation - The lead plaintiff in a class action is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [5]. - Members of the putative class can choose to serve as lead plaintiff or remain absent, with their ability to recover not affected by this decision [5]. Additional Information - Faruqi & Faruqi encourages anyone with information regarding Baxter's conduct, including whistleblowers and former employees, to contact the firm [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against James Hardie Industries plc for allegedly misleading investors regarding the performance of its North America Fiber Cement segment, with a class action lawsuit already filed [3][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in James Hardie between May 20, 2025, and August 18, 2025, to discuss their legal options [1][3]. - A federal securities class action has been filed against James Hardie, with a deadline of December 23, 2025, for investors to seek the role of lead plaintiff [3][5]. - The complaint alleges that James Hardie and its executives violated federal securities laws by making false statements and failing to disclose the true state of demand in their key segment [5]. Group 2: Financial Impact and Stock Performance - On August 19, 2025, James Hardie reported a 29% decline in first-quarter profit and projected lower-than-expected earnings for fiscal 2026 due to high borrowing costs [5]. - Following the announcement of disappointing financial results, the price of James Hardie's American Depositary Receipt (ADR) fell by $9.79, or 34.44%, closing at $18.64 on August 20, 2025 [6]. Group 3: Company Background and Contact Information - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding James Hardie's conduct [8].

Core Points - Faruqi & Faruqi, LLP is investigating potential claims against Cytokinetics, Incorporated, with a deadline for investors to seek lead plaintiff status in a federal securities class action by November 17, 2025 [1][3][6] - The complaint alleges that Cytokinetics made materially false and misleading statements regarding the New Drug Application (NDA) submission and approval process for aficamten, specifically about the expected FDA approval timeline [3][4] - The company failed to disclose significant risks related to the omission of a Risk Evaluation and Mitigation Strategy (REMS) from its NDA submission, which could delay the regulatory process [3][4] - Following the revelation of these issues during an earnings call on May 6, 2025, investors suffered significant losses as the stock price was artificially inflated prior to the disclosure [4][5] Company Information - Cytokinetics, Incorporated is facing legal scrutiny due to allegations of misleading investors regarding its drug approval process [1][3] - The firm Faruqi & Faruqi has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [2] Legal Proceedings - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of the class members [6] - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [6]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against WPP plc due to allegations of violations of federal securities laws related to misleading statements about the company's expected revenue for fiscal year 2025 [2][3]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in WPP between February 27, 2025, and July 8, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against WPP, with a deadline of December 8, 2025, for investors to seek the role of lead plaintiff [1][5]. Allegations Against WPP - The complaint alleges that WPP and its executives made false and misleading statements regarding the company's media division, claiming it was revitalizing and simplifying operations while concealing the true challenges it faced [2]. - Specific allegations include that WPP was losing significant market share and was not equipped to handle ongoing macroeconomic challenges, which were not disclosed to investors [2]. Market Reaction - Following WPP's trading update on July 9, 2025, which indicated a deterioration in performance, the company's stock price fell from $35.82 to $29.34, a decline of approximately 18.1% in one day [3][4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. due to allegations of false and misleading statements regarding the Novum LVP medical device, which has been linked to serious malfunctions and patient risks [3][4]. Group 1: Allegations Against Baxter - The complaint alleges that Baxter and its executives violated federal securities laws by failing to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion and overinfusion, exposing patients to serious injury or death [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [3]. - The company's statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Impact on Stock and Legal Proceedings - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, leading to a 22.4% drop in stock price, closing at $21.76 [4]. - Investors who purchased Baxter securities between February 23, 2022, and July 30, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi, with a deadline of December 15, 2025, to seek the role of lead plaintiff in the class action [1][5].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Firefly (FLY) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Firefly and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognize ...

Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation for allegedly making materially false and misleading statements regarding its business operations and financial prospects during the specified class period from February 18, 2025, to July 31, 2025 [3][7]. Allegation Details - The complaint claims that Fluor's management failed to disclose significant cost increases related to major projects, including the Gordie Howe, I-635/LBJ, and I-35 projects, due to subcontractor design errors, price hikes, and scheduling delays [3]. - It is alleged that these issues, along with reduced capital spending from customers and economic uncertainty, were likely to have a substantial negative impact on Fluor's business and financial results [3]. - The financial guidance provided by Fluor for FY 2025 is described as unreliable and unrealistic, with an overstated effectiveness of the company's risk mitigation strategies and an understated impact of economic uncertainty [3]. Next Steps - Investors who purchased Fluor shares and experienced losses are encouraged to contact the law firm Bragar Eagel & Squire for more information regarding their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 14, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across various courts in the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for allegedly making materially false and misleading statements regarding its business operations and financial prospects during the specified Class Period from August 8, 2024, to August 14, 2025 [8]. Allegation Details - The lawsuit claims that Nutex engaged in a scheme to defraud insurance companies through HaloMD, leading to unsustainable revenue [3]. - It is alleged that Nutex overstated its ability to remediate material weaknesses in its internal controls over financial reporting [3]. - The company reportedly misclassified stock-based compensation obligations, increasing the risk of failing to file timely financial reports with the SEC [3]. - Overall, the public statements made by Nutex were deemed materially false and misleading throughout the relevant period [3]. Next Steps - Investors who purchased Nutex shares and suffered losses are encouraged to contact the law firm for more information regarding their rights and potential claims [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 21, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a recognized law firm specializing in representing individual and institutional investors in complex litigation [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to alleged violations of federal securities laws, encouraging affected investors to contact them before the December 2, 2025 deadline for lead plaintiff applications in a federal securities class action [4][6]. Summary by Sections Company Overview - Molina Healthcare, Inc. is a publicly traded company on the NYSE under the ticker MOH [4]. Allegations and Financial Impact - The complaint alleges that Molina and its executives made false or misleading statements regarding the company's medical cost trend assumptions and financial guidance for fiscal year 2025 [6]. - Specific issues cited include a dislocation between premium rates and medical costs, reliance on low utilization of various health services, and the likelihood of cutting financial guidance [6]. Financial Results and Stock Performance - On July 7, 2025, Molina announced second-quarter results with adjusted earnings of approximately $5.50 per share, leading to a 10.2% cut in full-year earnings guidance from at least $24.50 to a range of $21.50 to $22.50 per share [7]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share [7]. - On July 23, 2025, Molina further reduced its full-year earnings guidance, reporting a GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year, and cutting guidance to no less than $19.00 per diluted share [8][9]. - This led to a significant stock price drop of $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [9]. Legal Proceedings - The deadline for investors to seek the role of lead plaintiff in the class action is December 2, 2025 [4]. - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [10]. Call for Information - Faruqi & Faruqi encourages anyone with information regarding Molina's conduct, including whistleblowers and former employees, to contact them [11].